BiotechTube

EOS789 + Placebo + Renvela

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia

Trial Timeline

Dec 1, 2016 → Aug 1, 2018

NCT ID
NCT02965053

About EOS789 + Placebo + Renvela

EOS789 + Placebo + Renvela is a phase 1 stage product being developed by Chugai Pharmaceutical for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02965053. Target conditions include Hyperphosphatemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02965053Phase 1Completed

Competing Products

20 competing products in Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
33
ASP1585 + Placebo + Sevelamer hydrochlorideAstellas PharmaPhase 2
52
ASP1585Astellas PharmaPhase 2
52
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlacebpKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 2
52
KHK7791 + PlaceboKyowa KirinPhase 3
77
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
23
KHK7791 + PlaceboKyowa KirinPhase 3
77
KHK7791Kyowa KirinPhase 3
77
KHK7791 + PlaceboKyowa KirinPhase 2
52
KHK7791Kyowa KirinPhase 3
77
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HClNovartisPhase 2
52
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
77
PA21Kissei PharmaceuticalPhase 3
76
Placebo + Sevelamer Carbonate (GZ419831)SanofiPhase 3
76
Placebo + Sevelamer carbonateSanofiPhase 2
51
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
20
Lanthanum Carbonate (Fosrenol, BAY77-1931)BayerPre-clinical
20
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
49

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77